20 publications

Name Date Type Actions

Universal registration document 2023 XBRL version

Universal Registration Document including the Annual Financial Report

 		24/04/2024 Reference document

Universal registration document 2023

Universal Registration Document including the Annual Financial Report

 		24/04/2024 Reference document

Universal registration document 2022

Universal Registration Document including the Annual Financial Report

 		05/05/2023 Reference document

Document d’enregistrement universel (URD) 2022 version XBRL

Document d'enregistrement universel 2022 incluant le rapport financier annuel

 		13/04/2023 Reference document

Universal registration document 2021

Universal Registration Document including the Annual Financial Report

 		05/05/2022 Reference document

2020 Universal registration document

2020 universal registration document including the Annual Financial Report

 		28/04/2021 Reference document

Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada

February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health.

 		08/02/2021 press release excluding results

2019 Universal registration document

Note to recipient of this document: this is the translation of an extract of the Universal Registration Document and Annual Financial Report for the year ended December 31, 2019. The original French document was filed with the AMF (French Financial Markets Authority) on April 23, 2020.

 		23/04/2020 Reference document

2018 registration document

Note to recipient of this document: this is the translation of an extract of the Registration Document and Annual Financial Report for the year ended December 31, 2018.

 		29/04/2019 Reference document

2017 Registration document

2017 Registration document

 		23/04/2018 Reference document

2016 Registration document

Note to recipient of this document: this is the translation of an extract of the Registration Document and Annual Financial Report for the year ended December 31, 2016. The original French document was filed with the AMF (French Financial Markets Authority) on April 26, 2017.

 		26/04/2017 Reference document

2015 Registration document

Note to recipient of this document: this is the translation of an extract of the Registration Document and Annual Financial Report for the year ended December 31, 2015. The original French document was filed with the AMF (French Financial Markets Authority) on April 26, 2016.

 		27/04/2016 Reference document

Registration Document 2014

Registration Document 2014

 		20/04/2015 Reference document

Reference Document 2013

Reference Document 2013

 		14/04/2014 Reference document

Reference Document 2012 (in french)

Reference Document 2012 (in french)

 		16/04/2013 Reference document

Reference document 2011

Reference document 2011

 		26/04/2012 Reference document

Reference document 2010

Reference document 2010

 		27/04/2011 Reference document

Reference Document 2009

Reference Document 2009

 		23/04/2010 Reference document

2008 financial report

Laboratoire pharmaceutique vétérinaire familial et indépendant, Vétoquinol se consacre exclusivement à la santé animale. Son activité est volontairement équilibrée entre animaux de rente et animaux de compagnie.
<br>
Historiquement implanté sur le marché français, le groupe réalise désormais 78% de son chiffre d'affaires consolidé à l'international (234,4 millions d'euros en 2008). Les 1400 collaborateurs du Groupe se répartissent entre la Recherche & Développement, la production et la commercilisation.
<br>
Aujourd'hui, la PME française -11e acteur mondial en santé animale (hors aliments)- produit et distribue 700 médicaments et produits non médicamenteux dans près de 100 pays (Europe, Amérique du Nord et Asie). Elle s'appuie sur ses filiales dans 22 pays et sur un réseau de 140 partenaires distributeurs.

 		04/05/2009 Reference document

Financial report 2007

Consolidated 2007 figures are even better than the targets in the business plan we presented for the initial public offering (IPO) in November 2006.
<br>
Revenues rose by 10.3% to 233.4 million euros (211.6 million euros in 2006), including 7.6% organic growth.
<br>
The operating profit from continuing operations increased by 13.9%, from 25.6 million euros in 2006 to 29.2 million euros in 2007.
<br>
Finally, net profit increased by 17.8% to 18.6 million euros in 2007 (15.8 million euros in 2006), for a net margin of 8% (7.5% the previous year).

 		15/05/2008 Reference document